<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2016-12-5-509-516</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-1329</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group></article-categories><title-group><article-title>Features of the Hemostasis and Platelets Enzyme Activity in Patients with Different Sensitivity to Acetylsalicylic Acid by the Acute Coronary Syndrome</article-title><trans-title-group xml:lang="ru"><trans-title>Особенности состояния гемостаза и активность ферментов в тромбоцитах у пациентов с разной чувствительностью к ацетилсалициловой кислоте при остром коронарном синдроме</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гринштейн</surname><given-names>И. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Grinshtein</surname><given-names>I. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., ассистент кафедры поликлинической терапии и семейной медицины КрасГМУ им. проф. В.Ф. Войно-Ясенецкого</p></bio><bio xml:lang="en"><p>MD, PhD, Teaching Assistant, Chair of Outpatient Therapy and Family Medicine, Krasnoyarsk State Medical University named after V.F. Voyno-Yasenetsky</p></bio><email xlink:type="simple">grinstein.yi@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Савченко</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Savchenko</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, зав. лабораторией клеточно-молекулярной физиологии и патологии НИИ медицинских проблем Севера СО РАМН; зав. кафедрой физиологии им. проф. А.Т. Пшоника КрасГМУ им. проф. В.Ф. Войно-Ясенецкого</p></bio><bio xml:lang="en"><p>MD, PhD, Professor, Head of Laboratory of Cell-Molecular Physiology and Pathology, Scientific Research Institute of Medical Problems of the North, Russian Academy of Medical Sciences; Head of Chair of Physiology named after Prof. A.T. Pshonik, Krasnoyarsk State Medical University named after V.F. Voyno-Yasenetsky</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гринштейн</surname><given-names>Ю. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Grinshtein</surname><given-names>Yu. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, зав. кафедрой терапии Института последипломного образования КрасГМУ им. проф. В.Ф. Войно-Ясенецкого</p></bio><bio xml:lang="en"><p>MD, PhD, Professor, Head of Chair of Therapy, Institute of Postgraduate Education, Krasnoyarsk State Medical University named after V.F. Voyno-Yasenetsky</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петрова</surname><given-names>М. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Petrova</surname><given-names>M. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, зав. кафедрой поликлинической терапии, семейной медицины и здорового образа жизни с курсом ПО, проректор по научной работе КрасГМУ им. проф. В.Ф. Войно-Ясенецкого</p></bio><bio xml:lang="en"><p>MD, PhD, Professor, Head of Chair of Outpatient Therapy, Family Medicine and Healthy Lifestyle, Vice-rector for Scientific Work, Krasnoyarsk State Medical University named after V.F. Voyno-Yasenetsky</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого Россия, 660022, Красноярск, пр. П. Железняка, 1А</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Krasnoyarsk State Medical University named after V.F. Voyno-Yasenetsky. Partizana Zheleznyaka ul. 1, Krasnoyarsk, 660022 Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого Россия, 660022, Красноярск, пр. П. Железняка, 1А&#13;
&#13;
Научно-исследовательский институт медицинских проблем Севера Россия, 660022, Красноярск, пр. П. Железняка, 3Г</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Krasnoyarsk State Medical University named after V.F. Voyno-Yasenetsky. Partizana Zheleznyaka ul. 1, Krasnoyarsk, 660022 Russia&#13;
&#13;
Scientific Research Institute of Medical Problems of the North. Partizana Zheleznyaka ul. 3G, Krasnoyarsk, 660022 Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>06</day><month>11</month><year>2016</year></pub-date><volume>12</volume><issue>5</issue><fpage>509</fpage><lpage>516</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Grinshtein I.Y., Savchenko A.A., Grinshtein Y.I., Petrova M.M., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Гринштейн И.Ю., Савченко А.А., Гринштейн Ю.И., Петрова М.М.</copyright-holder><copyright-holder xml:lang="en">Grinshtein I.Y., Savchenko A.A., Grinshtein Y.I., Petrova M.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/1329">https://www.rpcardio.online/jour/article/view/1329</self-uri><abstract><sec><title>Aim</title><p>Aim. To study the features of the state of hemostasis and platelet enzymes activity in acetylsalicylic acid (ASA) sensitive and resistant patients with acute coronary syndrome (ACS).</p></sec><sec><title>Material and methods</title><p>Material and methods. The study included 53 patients (25 men and 28 women) with ACS during the first 24 hours and after 10 days. The control group included 50 healthy volunteers. Before treatment the patients were tested on the sensitivity and resistance to ASA. The indicators of vascularplatelet and plasma hemostasis were evaluated as well as the NAD(P)- dependent dehydrogenases activity in platelets was assessed by the bioluminescent method in the first day of ACS before antiplatelet therapy and on day 10.</p></sec><sec><title>Results</title><p>Results. Increase in spontaneous [1.72 U (1.28-2.72 U) and 1.60 U (1.49-2.78 U), respectively] and ADP-induced [24.4% (21.1-29.8%) and 19.2% (16.1-22.9%), respectively] platelet aggregation, von Willebrand factor activity [159.0% (108.0-190.0%) and 155.0% (149.0-185.1%), respectively] was found in ASA-resistant patients with ACS in 1 and 10 day. Besides the ASA-resistant patients with ACS had very low pentose phosphate cycle and lactate dehydrogenase aerobic activity. They also demonstrated, compared with ASA-sensitive patients, higher intensity of aerobic respiration and the level of NADP-dependent substrate exchange between the tricarboxylic acid cycle and reactions of amino acid metabolism.</p></sec><sec><title>Conclusion</title><p>Conclusion. Despite the dual antiplatelet therapy with ASA and clopidogrel, risk of thrombotic events is saved in ASA resistant patients with ACS. The metabolic changes in platelet influence their aggregation activity and cause an inadequate response to the antiplatelet therapy in ACS patients.</p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>Цель</title><p>Цель. Изучить особенности состояния гемостаза и активности ферментов тромбоцитов у пациентов с острым коронарным синдромом (ОКС), чувствительных и резистентных к ацетилсалициловой кислоте (АСК).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Обследованы 53 пациента (25 мужчин и 28 женщин) с ОКС в первые 24 часа и через 10 суток. Контрольная группа – 50 здоровых добровольцев. Пациенты до начала лечения тестированы на чувствительность и резистентность к АСК. Изучались показатели сосудисто-тромбоцитарного и плазменного гемостаза, а также определена активность НАД(Ф)-зависимых дегидрогеназ в тромбоцитах крови биолюминесцентным методом в первые сутки ОКС до начала терапии дезагрегантами и на 10 сутки.</p></sec><sec><title>Результаты</title><p>Результаты. У АСК-резистентных пациентов в 1-е и 10-е сутки от развития ОКС установлено повышение спонтанной [1,72 (1,28-2,72) и 1,60 (1,49-2,78) усл. ед., соответственно] и АДФ-индуцированной [24,4% (21,1-29,8) и 19,2% (16,1-22,9), соответственно] агрегации тромбоцитов, активности фактора Виллебранда [159,0% (108,0-190,0) и 155,0% (149,0-185,1), соответственно]. Также у АСК-резистентных пациентов с ОКС выявлена очень низкая активность пентозофосфатного цикла и аэробная активность лактатдегидрогеназы, а также более высокая, чем у АСК-чувствительных пациентов интенсивность аэробного дыхания и уровень НАДФ-зависимого субстратного обмена между циклом трикарбоновых кислот и реакциями аминокислотного обмена.</p></sec><sec><title>Заключение</title><p>Заключение. Несмотря на применение комбинированной антитромбоцитарной терапии АСК и клопидогрелом риск тромбообразования у пациентов с ОКС, резистентных к АСК, сохраняется. Метаболические изменения в тромбоцитах отражаются на их агрегационной активности и вызывают у пациентов с ОКС недостаточный ответ на дезагреганты.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>острый коронарный синдром</kwd><kwd>чувствительность</kwd><kwd>резистентность</kwd><kwd>ацетилсалициловая кислота</kwd><kwd>тромбоциты</kwd><kwd>дегидрогеназы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>acute coronary syndrome</kwd><kwd>sensitivity</kwd><kwd>resistance</kwd><kwd>acetylsalicylic acid</kwd><kwd>platelets</kwd><kwd>dehydrogenases</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">GrinshteinYu.I., Savchenko A.A., GrinshteinI.Yu., Savchenko E.A. Features of hemostasis, platelet metabolic activity and the frequency of aspirin resistance in patients with chronic heart failure after coronary artery bypass grafting. Cardiology 2008; 48(6):51-56. In Russian (Гринштейн Ю.И.; Савченко А.А.; Гринштейн И.Ю.; Савченко Е.А. Особенности гемостаза, метаболической активности тромбоцитов и частота резистентности к аспирину у больных с хронической сердечной недостаточностью после аортокоронарного шунтирования. Кардиология 2008; 48(6):51-56).</mixed-citation><mixed-citation xml:lang="en">GrinshteinYu.I., Savchenko A.A., GrinshteinI.Yu., Savchenko E.A. Features of hemostasis, platelet metabolic activity and the frequency of aspirin resistance in patients with chronic heart failure after coronary artery bypass grafting. Cardiology 2008; 48(6):51-56. In Russian (Гринштейн Ю.И.; Савченко А.А.; Гринштейн И.Ю.; Савченко Е.А. Особенности гемостаза, метаболической активности тромбоцитов и частота резистентности к аспирину у больных с хронической сердечной недостаточностью после аортокоронарного шунтирования. Кардиология 2008; 48(6):51-56).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Liu X.F., Cao J., Fan L., Liu L., Li J., Hu G.L., Hu Y.X., Li X.L. Prevalence of and risk factors for aspirin resistance in elderly patients with coronary artery disease. J Geriatr Cardiol 2013; 10 (1): 21-7.</mixed-citation><mixed-citation xml:lang="en">Liu X.F., Cao J., Fan L., Liu L., Li J., Hu G.L., Hu Y.X., Li X.L. Prevalence of and risk factors for aspirin resistance in elderly patients with coronary artery disease. J Geriatr Cardiol 2013; 10 (1): 21-7.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">ESC Guidelines For the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal 2011; 32: 2999-3054.</mixed-citation><mixed-citation xml:lang="en">ESC Guidelines For the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal 2011; 32: 2999-3054.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">GrinshteinYu.I.; Filonenko I.V.; Savchenko A.A. et al. A method for diagnosing resistance to acetylsalicylic acid. Patent № 2413953 Russia, MPK G01N 33/86 (2006.01). Published 10.03.2009, Bul. № 7. Russian (Гринштейн Ю.И.; Филоненко И.В.; Савченко А.А. и др. Способ диагностики резистентности к ацетилсалициловой кислоте. Патент № 2413953 РФ, МПК G01N 33/86 (2006.01). Опубл. 10.03.2009, Бюл. № 7).</mixed-citation><mixed-citation xml:lang="en">GrinshteinYu.I.; Filonenko I.V.; Savchenko A.A. et al. A method for diagnosing resistance to acetylsalicylic acid. Patent № 2413953 Russia, MPK G01N 33/86 (2006.01). Published 10.03.2009, Bul. № 7. Russian (Гринштейн Ю.И.; Филоненко И.В.; Савченко А.А. и др. Способ диагностики резистентности к ацетилсалициловой кислоте. Патент № 2413953 РФ, МПК G01N 33/86 (2006.01). Опубл. 10.03.2009, Бюл. № 7).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Savchenko E.A.; Savchenko A.A.; Gerasimchuk A.N.; Grishhenko D.A. Evaluation of the metabolic status of platelets in normal and ischemic heart disease. Klinicheskaja laboratornaja diagnostika 2006; 5: 33-6. Russian (Савченко Е.А.; Савченко А.А.; Герасимчук А.Н.; Грищенко Д.А. Оценка метаболического статуса тромбоцитов в норме и при ишемической болезни сердца. Клиническая лабораторная диагностика 2006; 5: 33-6).</mixed-citation><mixed-citation xml:lang="en">Savchenko E.A.; Savchenko A.A.; Gerasimchuk A.N.; Grishhenko D.A. Evaluation of the metabolic status of platelets in normal and ischemic heart disease. Klinicheskaja laboratornaja diagnostika 2006; 5: 33-6. Russian (Савченко Е.А.; Савченко А.А.; Герасимчук А.Н.; Грищенко Д.А. Оценка метаболического статуса тромбоцитов в норме и при ишемической болезни сердца. Клиническая лабораторная диагностика 2006; 5: 33-6).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Severin E.S., Alejnikova T.L., Osipov E.V., Silaeva S.A. Biological chemistry. Moscow: MIA; 2008. In Russian (Северин Е.С., Алейникова Т.Л., Осипов Е.В., Силаева С.А. Биологическая химия. М.: МИА; 2008).</mixed-citation><mixed-citation xml:lang="en">Severin E.S., Alejnikova T.L., Osipov E.V., Silaeva S.A. Biological chemistry. Moscow: MIA; 2008. In Russian (Северин Е.С., Алейникова Т.Л., Осипов Е.В., Силаева С.А. Биологическая химия. М.: МИА; 2008).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Borna C.; Lazarowski E.; van Heusden C. et al. Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb J 2005; 3: 10.</mixed-citation><mixed-citation xml:lang="en">Borna C.; Lazarowski E.; van Heusden C. et al. Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb J 2005; 3: 10.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Grinshtein Yu.I.; Kosinova A.A.; Grinshtein I.Yu. The possible causes and mechanisms of development of secondary acetylsalicylic acid resistance. Rossijskie medicinskie vesti 2013; 2: 4-13. Russian (Гринштейн Ю.И.; Косинова А.А.; Гринштейн И.Ю. Возможные причины и механизмы развития вторичной резистентности к ацетилсалициловой кислоте. Российские медицинские вести 2013; 2: 4-13).</mixed-citation><mixed-citation xml:lang="en">Grinshtein Yu.I.; Kosinova A.A.; Grinshtein I.Yu. The possible causes and mechanisms of development of secondary acetylsalicylic acid resistance. Rossijskie medicinskie vesti 2013; 2: 4-13. Russian (Гринштейн Ю.И.; Косинова А.А.; Гринштейн И.Ю. Возможные причины и механизмы развития вторичной резистентности к ацетилсалициловой кислоте. Российские медицинские вести 2013; 2: 4-13).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Chakroun T.; Gerotziafas G.; Robert F. et al. In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br J Haematol 2004; 124 (1): 80- 5.</mixed-citation><mixed-citation xml:lang="en">Chakroun T.; Gerotziafas G.; Robert F. et al. In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br J Haematol 2004; 124 (1): 80- 5.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Luzzatto L., Nannelli C., Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Hematol Oncol Clin North Am 2016; 30(2): 373-93.</mixed-citation><mixed-citation xml:lang="en">Luzzatto L., Nannelli C., Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Hematol Oncol Clin North Am 2016; 30(2): 373-93.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Sato T., Morita A., Mori N., Miura S. Glycerol 3-phosphate dehydrogenase 1 deficiency enhances exercise capacity due to increased lipid oxidation during strenuous exercise. Biochem Biophys Res Commun 2015; 457(4): 653-8.</mixed-citation><mixed-citation xml:lang="en">Sato T., Morita A., Mori N., Miura S. Glycerol 3-phosphate dehydrogenase 1 deficiency enhances exercise capacity due to increased lipid oxidation during strenuous exercise. Biochem Biophys Res Commun 2015; 457(4): 653-8.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Sledzinski T., Korczynska J., Goyke E., et al. Association between cytosolic glycerol 3-phosphate dehydrogenase gene expression in human subcutaneous adipose tissue and BMI. Cell Physiol Biochem 2013; 32(2): 300-9.</mixed-citation><mixed-citation xml:lang="en">Sledzinski T., Korczynska J., Goyke E., et al. Association between cytosolic glycerol 3-phosphate dehydrogenase gene expression in human subcutaneous adipose tissue and BMI. Cell Physiol Biochem 2013; 32(2): 300-9.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Liu L., Shah S., Fan J., et al. Malic enzyme tracers reveal hypoxia-induced switch in adipocyte NADPH pathway usage. Nat Chem Biol 2016; 12(5): 345-52.</mixed-citation><mixed-citation xml:lang="en">Liu L., Shah S., Fan J., et al. Malic enzyme tracers reveal hypoxia-induced switch in adipocyte NADPH pathway usage. Nat Chem Biol 2016; 12(5): 345-52.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia-Souza L.F., Oliveira M.F. Mitochondria: biological roles in platelet physiology and pathology. Int J Biochem Cell Biol 2014; 50: 156-60.</mixed-citation><mixed-citation xml:lang="en">Garcia-Souza L.F., Oliveira M.F. Mitochondria: biological roles in platelet physiology and pathology. Int J Biochem Cell Biol 2014; 50: 156-60.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Z., Wang J., Xie R, et al. Mitochondria-derived reactive oxygen species play an important role in Doxorubicin-induced platelet apoptosis. Int J Mol Sci 2015; 16 (5): 11087-100.</mixed-citation><mixed-citation xml:lang="en">Wang Z., Wang J., Xie R, et al. Mitochondria-derived reactive oxygen species play an important role in Doxorubicin-induced platelet apoptosis. Int J Mol Sci 2015; 16 (5): 11087-100.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Korla K., Vadlakonda L., Mitra C.K. Kinetic simulation of malate-aspartate and citrate-pyruvate shuttles in association with Krebs cycle. J Biomol Struct Dyn 2015; 33(11): 2390-403.</mixed-citation><mixed-citation xml:lang="en">Korla K., Vadlakonda L., Mitra C.K. Kinetic simulation of malate-aspartate and citrate-pyruvate shuttles in association with Krebs cycle. J Biomol Struct Dyn 2015; 33(11): 2390-403.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Wang C., Chen H., Zhang J., et al. Malate-aspartate shuttle mediates the intracellular ATP levels, antioxidation capacity and survival of differentiated PC12 cells. Int J Physiol Pathophysiol Pharmacol 2014; 6(2): 109-14.</mixed-citation><mixed-citation xml:lang="en">Wang C., Chen H., Zhang J., et al. Malate-aspartate shuttle mediates the intracellular ATP levels, antioxidation capacity and survival of differentiated PC12 cells. Int J Physiol Pathophysiol Pharmacol 2014; 6(2): 109-14.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Lee Y.J., Kim K.J., Kang H.Y., et al. Involvement of GDH3-encoded NADP+-dependent glutamate dehydrogenase in yeast cell resistance to stress-induced apoptosis in stationary phase cells. J Biol Chem 2012; 287(53): 44221-33.</mixed-citation><mixed-citation xml:lang="en">Lee Y.J., Kim K.J., Kang H.Y., et al. Involvement of GDH3-encoded NADP+-dependent glutamate dehydrogenase in yeast cell resistance to stress-induced apoptosis in stationary phase cells. J Biol Chem 2012; 287(53): 44221-33.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
